Larimar Therapeutics, Inc.
LRMRDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How LRMR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nomlabofusp | Phase 3 | Friedreich Ataxia | - | - |
CTI-1601 | Phase 2 | Friedreich Ataxia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Larimar Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Larimar Therapeutics, Inc.'s (LRMR) pipeline across Phase 3, Phase 2. Its lead program is Nomlabofusp (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Larimar Therapeutics, Inc.'s next FDA catalyst?→
Larimar Therapeutics, Inc.'s (LRMR) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LRMR biotech catalysts?→
Add LRMR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Larimar Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.